[ad_1]
BEVERLY HILLS, CA – 
Bryan Therapeutics, Inc. (BTI) is represented for Media Strategy Positioning by Creative Management Partners LLC (CMP), Beverly Hills, CA. Additionally, Dr. Bryan’s Authored book “Nathan S. Bryan, Ph.D, The Secret Of Nitric Oxide—Bringing Nitric Oxide To Life”, sold to J. Boylston & Company Publishers, to be released in early 2024, represented by Agent Alan Morell, Creative Management Partners LLC (CMP) to support BTI endeavors.
Said Dr. Nathan Bryan Ph.D., Founder, Chairman and CEO of BTI, “During the past few years, we have outgrown our previous corporate structure. Our objective has not changed but our strategy has changed. BTI is ideally positioned to continue to advance the science of nitric oxide into safe and effective drug therapies. Our recent COVID drug study established the safety of our oral nitric oxide drug and now we are moving into the next phase of clinical trials for several indications. This requires additional capital and a broader team with experience in global distribution and drug development. We have assembled the best team in the business to get our drugs through clinical trials, approved in major markets and in the hands of physicians and patients to improve lives around the world. Our strategy with NOI was to move our nitric oxide technology into clinical trials, de-risk it and then sell or license to a larger company. Now that we have established safety of our oral formulation, we can quickly, efficiently, and cost effectively advance our drugs through clinical trials for approval. BTI’s strategy is to see drugs through FDA approval and be the market leader in nitric oxide-based drugs and therapeutics. We are confident we have the right people, the best technology and sufficient capital to get our drugs approved for many poorly managed chronic diseases.”
BTI has plans to submit investigational new drug applications (INDs) for ischemic heart disease in the coming weeks. BTI has active drug programs for Alzheimers’ disease and a topical drug for diabetic/pressure ulcers. Additional development plans for ischemic, non-obstructive coronary artery disease, pulmonary hypertension, heart failure with preserved ejection fraction (HFpEF). David Perlmutter, M.D., Director of Neuroscience Research says, “BTI is uniquely positioned to implement novel therapeutic strategies utilizing the emerging understanding of the central role of nitric oxide in regulating human metabolism. This is incredibly relevant across a wide spectrum of disease processes, including Alzheimer’s disease, and cardiovascular disorders.”
Said John Somberg, M.D., President of Academic Pharmaceuticals and Professor Emeritus of Medicine Cardiology in Pharmacology Rush Medical College, Chicago; “I’ve conducted more than 40 FDA clinical trials for many different therapeutics. I believe that nitric oxide has a major place in therapeutics, and I think if anyone is going to bring it to fruition it is Bryan Therapeutics, Inc. The basic science behind nitric oxide therapies is solid. Now, it is time for the development of safe and effective nitric oxide therapeutics. Dr. Bryan’s science and discoveries have great potential and I’m excited to be involved.”
For investment opportunities and to receive a private placement memorandum, please contact Dr. Nathan S Bryan at nathan@bryantherapeutics.com
ABOUT BRYAN THERAPEUTICS, INC. (BTI) AND NATHAN S. BRYAN PH.D:
Bryan Therapeutics, Inc (BTI) was established to commercialize clinically, and scientifically proven Nitric Oxide (NO) based technologies for a wide range of human disease and conditions. Our mission is to be the industry leader and innovator in nitric oxide-based technologies in order to bring to market safe and effective therapeutic solutions where NO may be involved. Our vision for BTI is to be the market leader in nitric oxide-based therapeutics. BTI has drug programs for ischemic heart disease, Alzheimers’ Disease, topical drugs for diabetic and pressure ulcers as well as a novel antiviral in the event of another pandemic.
Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University Health Sciences Center in Shreveport where he was the recipient of the Dean’s Award for Excellence in Research. He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute. After a two year post-doctoral fellowship, in 2006 Dr. Bryan was recruited to join faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology. Dr. Bryan has been involved in nitric oxide research for the past 20 years and has made many seminal discoveries in the field. His many seminal discoveries have resulted in dozens of issued US and International patents and the product technology resulting from his discoveries and inventions has improved patient care worldwide and is responsible for hundreds of millions of dollars in revenue globally. Dr. Bryan is the inventor of Superbeets, Neo40, BeetElite, NO2U, N1O1 nitric oxide activating serum. His nitric oxide products are the global market leaders. Dr. Bryan is an international leader in molecular medicine and nitric oxide biochemistry.
For further information go to:
BLOGSITE: drperlmutter.com
Instagram: @DRNATHANSBRYAN
Dr. Nathan S. Bryan
Bryan Therapeutics, Inc Drug Company Founder, CEO and Chairman of the Board
Contact Information:
THE CREATIVE MANAGEMENT AGENCY
Creative Management Partners LLC (CMP)
Beverly Hills Gardens Building
9440 Santa Monica Blvd. Suite 301,
Beverly Hills, Ca. 90210 / 508-292-7900
www.creativemanagementpartners.com
View the original release on www.newmediawire.com
[ad_2]